`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MINNESOTA
`
`
`
`BCBSM, Inc., Health Care Service
`Corporation, Molina Healthcare, Inc., and
`Blue Cross and Blue Shield of Florida, Inc.,
`
`
`
`v.
`
`Celgene Corporation and Bristol-Myers
`Squibb Company,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. 0:20-cv-02071-SRN-ECW
`
`HON. SUSAN RICHARD NELSON
`HON. ELIZABETH COWAN WRIGHT
`
`
`
`Plaintiffs,
`
`Defendants.
`
`
`
`MEMORANDUM OF LAW IN SUPPORT OF
`DEFENDANTS’ MOTION TO DISMISS PURSUANT TO RULE 12(b)(6)
`
`
`
`
`CASE 0:20-cv-02071-SRN-ECW Doc. 47 Filed 12/04/20 Page 2 of 49
`
`TABLE OF CONTENTS
`
`TABLE OF AUTHORITIES .............................................................................................. iv
`
`INTRODUCTION ............................................................................................................... 1
`
`BACKGROUND ................................................................................................................. 2
`
`LEGAL STANDARDS ....................................................................................................... 6
`
`ARGUMENT ....................................................................................................................... 7
`
`I.
`
`PLAINTIFFS’ ANTITRUST THEORIES FAIL ..................................................... 9
`
`A.
`
`The Antitrust Theories in Counts I-IV Are Contrary To Law. ..................... 9
`
`1.
`
`2.
`
`3.
`
`4.
`
`Refusals to Deal. ................................................................................ 9
`
`Sham Litigation. ............................................................................... 11
`
`a.
`
`Litigations on the Thalomid Patents. .................................... 12
`
`1)
`
`2)
`
`Lannett Litigation. ...................................................... 12
`
`Barr Litigation. ........................................................... 14
`
`b.
`
`Litigations on the Revlimid Patents. ..................................... 15
`
`1)
`
`2)
`
`Natco Litigation. ........................................................ 17
`
`Other patent infringement suits. ................................. 17
`
`c.
`
`The Distribution Method Patents. ......................................... 18
`
`Patent Settlements ............................................................................ 19
`
`Plaintiffs Lack Any Antitrust Injury ................................................ 21
`
`a.
`
`b.
`
`Plaintiffs Fail to Adequately Plead That All of Celgene’s
`Patent Claims are Shams ....................................................... 22
`
`Plaintiffs Fail to Plead that Any Generic Has Obtained FDA
`Approval ................................................................................ 22
`
`B.
`
`Plaintiffs’ Antitrust Claims Fail Under Several Applicable State Laws. .... 23
`
`1.
`
`Plaintiffs Cannot Proceed under Certain States’ Antitrust Laws as
`Indirect Purchasers (Counts I & II). ................................................. 23
`
`

